Investigational Drug Details
| Drug ID: | D453 |
| Drug Name: | Apixaban |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB06605 |
| DrugBank Description: | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012[L6043]. |
| PubChem ID: | 10182969 |
| CasNo: | 503612-47-3 |
| Repositioning for NAFLD: | Yes |
| SMILES: | COC1=CC=C(C=C1)N1N=C(C(N)=O)C2=C1C(=O)N(CC2)C1=CC=C(C=C1)N1CCCCC1=O |
| Structure: |
|
| InChiKey: | QNZCBYKSOIHPEH-UHFFFAOYSA-N |
| Molecular Weight: | 459.4971 |
| DrugBank Targets: | Coagulation factor X |
| DrugBank MoA: | Apixaban selectively inhibits factor Xa in its free and bound forms, independant of antithrombin III[Label]. Apixaban also inhibits prothrominase[Label]. These effects prevent the formation of a thrombus[Label]. |
| DrugBank Pharmacology: | Apixaban selectively inhibits factor Xa in its free and bound forms, independant of antithrombin III[Label]. Apixaban also inhibits prothrominase[Label]. These effects prevent the formation of a thrombus[Label]. |
| DrugBank Indication: | Apixaban is indicated for reducing the risk of stroke and systemic embolism in patients who have nonvalvular atrial fibrillation, prophylaxis of deep vein thrombosis(DVT) leading to pulmonary embolism(PE) in patients after a hip or knee replacement surgery, and treatment of DVT and PE to reduce the risk of recurrence[Label,A177565,A6897]. |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0393 | NCT01424319 | PHASE2 | COMPLETED | NO | 2011-08 | 2017-08-29 | Details |
| L2322 | NCT00205725 | COMPLETED | NO | 2000-11 | 2014-03-13 | Details | |
| L2460 | NCT00846391 | PHASE2 | TERMINATED | YES | 2008-12 | 2016-02-05 | Details |
| L2493 | NCT00478972 | PHASE3 | TERMINATED | NO | 2007-04 | 2016-06-08 | Details |
| L3298 | NCT02607865 | PHASE3 | COMPLETED | YES | 2016-02-15 | 2022-07-20 | Details |
| L3433 | NCT01542463 | COMPLETED | NO | 2004-09 | 2016-03-03 | Details | |
| L3456 | NCT01959334 | PHASE3 | COMPLETED | YES | 2013-09 | 2019-09-06 | Details |
| L3458 | NCT00664534 | PHASE4 | COMPLETED | YES | 2008-04 | 2011-12-13 | Details |
| L3778 | NCT02078440 | PHASE1 | COMPLETED | NO | 2014-01 | 2016-08-29 | Details |
| L4284 | NCT02650596 | UNKNOWN | NO | 2016-01 | 2016-01-08 | Details | |
| L4298 | NCT01490658 | PHASE1 | COMPLETED | NO | 2006-06 | 2017-02-10 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|